# Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

> **NCT03568331** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 375 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tradipitant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03568331
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2019-12-27
- **Final completion:** 2019-12-27
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568331, "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03568331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*